Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Long-term Persistence of Immunity to Hepatitis B, in Adolescents Vaccinated in Infancy With Engerix™-B Kinder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject's parent(s)/guardians who, in the opinion of the investigator, can and will comply, with the requirements of the protocol.~* A male or female between, and including, 15 and 16 years of age at the time of the vaccination.~* Written informed consent obtained from the parent(s)/LAR(s) of the subject.~* Written informed assent obtained from the subject in addition to the informed consent signed by the parent(s)/LAR(s).~* Healthy subjects as established by medical history and clinical examination before entering into the study.~* Documented evidence of previous vaccination with three consecutive doses of Engerix™-B Kinder in Germany: with the first two doses received by 9 months of age and the third dose received by 18 months of age.~* Female subjects of non-childbearing potential may be enrolled in the study.~  * Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause.~* Female subjects of childbearing potential may be enrolled in the study, if the subject:~  * has practiced adequate contraception for 30 days prior to vaccination, and~ * has a negative pregnancy test on the day of vaccination, and~ * has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination.~Exclusion Criteria:~* Child in care.~* Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the dose of study vaccine, or planned use during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the vaccine dose. For corticosteroids, this will mean prednisone ≥ 20 mg/day, or equivalent. Inhaled and topical steroids are allowed.~* Previous hepatitis B vaccination since administration of the third dose of Engerix™-B Kinder.~* History of hepatitis B disease.~* Administration of a vaccine not foreseen by the study protocol within the period starting 30 days before study vaccine dose, or planned administration during the study period.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product.~* History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~* Acute disease and/or fever at the time of enrollment.~  * Fever is defined as temperature ≥ 37.5°C for oral, axillary or tympanic route, or ≥ 38.0°C on rectal route. The preferred route for recording temperature in this study will be axillary.~ * Subjects with a minor illness without fever may be enrolled at the discretion of the investigator.~* Administration of immunoglobulins and/or any blood products within the 3 months preceding the study vaccine dose or planned administration during the study period.~* Pregnant or lactating female.~* Female planning to become pregnant or planning to discontinue contraceptive precautions.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 16 Years
- Healthy Volunteers: t

Study Arms:
- HBV Group (Type: EXPERIMENTAL): Subjects received a single dose of Engerix™-B Kinder vaccine (HBV). The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete